ROSSI CARLO RICCARDO

Contacts
E-mail
444053eda9ea5855777ad7ea0fe89861
bring this page
with you
Structure Department of Surgery, Oncology and Gastroenterology
Telephone 0498212070
Qualification Professore ordinario
Scientific sector MED/18 - GENERAL SURGERY
University telephone book  Show
 

Office hours
Monday from 12:30 to 13:30 Studio prof. Carlo Riccardo Rossi - IOV, via Gattamelata 64 (1 piano IOV) Per conferma dell'orario di ricevimento, contattare la segreteria allo 049 8212137.
(updated on 27/10/2017 13:16)

Proposals for thesis
In relazione alle aree di ricerca.

Curriculum Vitae
Personal data
Date and place of birth: Rosolina (RO), Italy - March 5, 1950
Work address: Melanoma and Sarcoma Unit, Venetian Institute of Oncology - University of Padova, Via Gattamelata 64, 35128 Padova - Italy
Education
Graduated at: University of Padova Medical School, Italy (1975)
Degree: Medical Doctor, University of Padova Medical School, Italy
Specializations: General Surgery, University of Padova Medical School, Italy (1981); Oncology, University of Padova, Italy (1984)
Principal position
Since 2015 Director of Surgical Oncology Unit at Veneto Institute of Oncology (Padova)
Since 2010 Full Professor of Surgery at the Dept. of Surgical, Oncologic and Gastroenterological Sciences of Padova University
Since 2004 Chief of the Melanoma and Sarcomas Unit at the Dept. of Surgical, Oncologic and Gastroenterological Sciences of Padova University.
Since 1981 he has been Surgeon. So far, he has performed more than 4500 surgical interventions.
1975-1981: Resident, Dept. of general Surgery, at University of Padova.
Professional expertise
He is particularly involved in tumor immunology, anticancer active specific immunotherapy (cancer vaccines) and the study of tumor microenvironment during biological therapies (e.g. immunotherapy, TNF, IL-2, IFN). Other active areas of research are mechanisms of tumor responsiveness to biological therapies (e.g. immunotherapy, TNF, IL-2, IFN) both in vitro and in vivo (in humans), identification of novel prognostic and predictive factors, and development of tumor-specific patient-tailored molecularly targeted treatments. Finally, he is involved in the definition of cancer management guidelines by means of implementation of statistically intensive methodologies such as meta-analysis, support vector machine learning models and so on.
He is also involved in medical (mainly adjuvant and neoadjuvant chemotherapy) and surgical treatment of solid tumors, with special regard to melanoma, soft tissue sarcomas and peritoneal carcinomatosis. He is also involved in locoregional treatments (e.g. isolated limb perfusion, isolated hepatic perfusion, hyperthermic intraoperative intraperitoneal chemotherapy) for locally advanced solid tumors. Finally, he is interested in advanced biostatistics (e.g. predictive models, survival analysis, meta-analysis), methodological and statistical aspects of clinical trial design and clinical implementation of the so called molecularly targeted therapy.
His main interest has been devoted to Surgical Oncology for solid tumors, in particular to cutaneous melanoma, soft tissue sarcomas, peritoneal carcinomatosis and locoregional treatment.
Since 1978, he is the Author of 208 scientific publications published on international journals (Total Impact Factor: 895.179; H-index:42).

Lecturer's Curriculum (PDF): 444053EDA9EA5855777AD7EA0FE89861.pdf

Research areas
MEDICINA ONCOLOGICA PERSONALIZZATA E TERAPIE INNOVATIVE

La medicina oncologica personalizzata prevede tre momenti fondamentali:
- Diagnostica oncologica di precisione (precision oncology) che ha l’obiettivo di caratterizzare la neoplasia ed individuare i fattori biomolecolari del tumore in grado di predire la prognosi e la risposta alle terapie, con l’utilizzo delle più moderne metodiche di diagnostica molecolare
- La personalizzazione del trattamento oncologico basato sulle caratteristiche di genere, di età, di comorbidità, di farmacogenomica e del profilo psicologico del singolo paziente.

L’attività di ricerca comprende:
- Disegno di studi clinici con trattamenti innovativi sulla base di studi condotti su modelli preclinici.
- Raccolta dei campioni biologici e “biobanking”
- Applicazione di tecniche di diagnostica molecolare avanzata
- Creazione di database di dati biologici e clinici e applicazione di tecniche statistiche
- Disegno di studi clinici sulla base di caratterizzazione biomolecolare e che includano anche obiettivi di ricerca traslazionale e “Patient Reported Outcomes”.

APPROCCIO MULTIDISCIPLINARE ALLA MALATTIA ONCOLOGICA AVANZATA

Nonostante i progressi, la maggior parte dei pazienti con diagnosi di tumore muore per malattia metastatica. Esiste un oggettivo ritardo nel trasferimento nella pratica clinica dei progressi e delle conoscenze dovuto principalmente a due fattori:
- La caratterizzazione biologica delle neoplasie viene fatta quasi esclusivamente su tumori primitivi, mentre invece sono poco conosciuti i fattori prognostici e predittivi della malattia metastatica
- A fronte di grandi progressi delle terapie locoregionali e della diagnostica con “imaging” avanzato, mancano studi prospettici che valutino l’integrazione secondo un approccio multimodale.
Inoltre, considerando il processo di cronicizzazione di molte patologie oncologiche, acquisisce sempre maggior rilevanza lo studio sistematico della qualità della vita mediante la valutazione multidimensionale.

Pertanto, l’attività di ricerca si basa su:
- Biobanking di tessuto metastatico e/o cellule tumorali circolanti
- Caratterizzazione molecolare di tessuto metastatico e/o cellule tumorali circolanti
- Disegno di studi clinici prospettici basati sul trattamento multidisciplinare integrato delle malattie oncologiche avanzate
- Valutazione muldimensionale della qualità della vita di pazienti sottoposti a trattamenti multimodali integrati.

Publications
GERSHENWALD JE, SCOLYER RA, HESS KR, SONDAK VK, LONG GV, ROSS MI, LAZAR AJ, FARIES MB, KIRKWOOD JM, MCARTHUR GA, HAYDU LE, EGGERMONT AMM, FLAHERTY KT, BALCH CM, THOMPSON JF; For members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform.
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
CA Cancer J Clin. 2017 Nov;67(6):472-492.

BENNA C, SIMIONI A, PASQUALI S, DE BONI D, RAJENDRAN S, SPIRO G, COLOMBO C, VIRGONE C, DUBOIS SG, GRONCHI A, ROSSI CR, MOCELLIN S.
Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis.
Oncotarget. 2018 Apr 6;9(26):18607-18626.

ONGARO A, CAMPANA LG, DE MATTEI M, DI BARBA P, DUGHIERO F, FORZAN M, MOGNASCHI ME, PELLATI A, ROSSI CR, BERNARDELLO C, SIENI E.
Effect of Electrode Distance in Grid Electrode: Numerical Models and In Vitro Tests.
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818764498.

MOCELLIN S, TROPEA S, BENNA C, ROSSI CR.
Circadian pathway genetic variation and cancer risk: evidence from genome-wide association studies.
BMC Med. 2018 Feb 19;16(1):20. doi: 10.1186/s12916-018-1010-1.

ROSSI CR, SOMMARIVA A, BASTIAANNET E, VAN DE VELDE CJH.
Quality assurance and sustainability of cancer care: A European network is needed.
Eur J Surg Oncol. 2018 Apr;44(4):383-385.

PASQUALI S, HADJINICOLAOU AV, CHIARION SILENI V, ROSSI CR, MOCELLIN S.
Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev. 2018 Feb 6;2:CD011123.

BUJA A, SARTOR G, SCIONI M, VECCHIATO A, BOLZAN M, REBBA V, SILENI VC, PALOZZO AC, MONTESCO M, DEL FIORE P, BALDO V, ROSSI CR.
Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines.
Acta Derm Venereol. 2018 Feb 7;98(2):218-224.

ROSSI CR, MOCELLIN S, CAMPANA LG, BORGOGNONI L, SESTINI S, GIUDICE G, CARACÒ C, CORDOVA A, SOLARI N, PIAZZALUNGA D, CARCOFORO P, QUAGLINO P, CALIENDO V, RIBERO S; Italian Melanoma Intergroup (IMI).
Prediction of Non-sentinel Node Status in Patients with Melanoma and Positive Sentinel Node Biopsy: An Italian Melanoma Intergroup (IMI) Study.
Ann Surg Oncol. 2018 Jan;25(1):271-279.

SOMMARIVA A, EVANGELISTA L, PINTACUDA G, CERVINO AR, RAMONDO G, ROSSI CR.
Diagnostic value of contrast-enhanced CT combined with 18-FDG PET in patients selected for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Abdom Radiol (NY). 2018 May;43(5):1094-1100.

Lecturer's Publications (PDF): 444053EDA9EA5855777AD7EA0FE89861.pdf

List of taught course units in A.Y. 2019/20
Degree course code (?) Degree course track Course unit code Course unit name Credits Year Period Lang. Teacher in charge
ME1727 COMMON MEP3054043 12 6th Year (2019/20) Annual ITA CARLO RICCARDO ROSSI


Responsibility of other activity for A.Y. 2019/20
Degree course code (?) Degree course track Course unit code Course unit name Credits Year Period Lang. Teacher in charge
ME1727 COMMON MEP9088518 5 6th Year (2019/20) Annual ITA CARLO RICCARDO ROSSI